AndreasGiannakouMD

General Surgery • Washington, DC

Breast

Physician

Join to view full profile

Dr. Giannakou is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Giannakou's full profile

Already have an account?

Office
4832 Reno Rd NW
Washington, DC 20008
Phone+1 973-580-2753

Education & Training

Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Breast Surgical Oncology, 2023 - 2024
Massachusetts General HospitalFellowship, Breast Surgical Oncology, 2023 - 2024
University of RochesterResidency, Surgery, 2020 - 2023
University of Pennsylvania Health SystemResidency, Surgery, 2018 - 2020
National Institutes of Health Clinical CenterFellowship, Research, 2016 - 2018
University of AthensClass of 2013

Certifications & Licensure

NY State Medical License 2024 - 2026
MA State Medical License 2023 - 2024

Publications & Presentations

PubMed

90 citations
Purine Nucleotide Availability Regulates mTORC1 Activity through the Rheb GTPase
Natasha Emmanuel, Shoba Ragunathan, Qin Shan, Fang Wang, Andreas Giannakou
Cell Reports. 2017-06-27
6 citations
Do patients with familial nonmedullary thyroid cancer present with more aggressive disease? Implications for initial surgical treatment.
Mustapha El Lakis, Andreas Giannakou, Pavel J Nockel, Douglas Wiseman, Sudheer Kumar Gara
Surgery. 2019-01-01
47 citations
Cancer-associated fibroblasts suppress SOX2-induced dysplasia in a lung squamous cancer coculture.
Shuang Chen, Andreas Giannakou, Sarah Wyman, Janet Gruzas, Jonathon Golas
Proceedings of the National Academy of Sciences of the United States of America. 2018-12-11

Press Mentions

Could Cranial Ultrasound Sub for Brain MRI in Imaging Infants?November 6th, 2024
Ultrasound Nonmass Breast Lesion Features May Signal MalignancyNovember 5th, 2024
Volpara Secures 5-Year, $7.3M U.S. Defense Health Agency ContractNovember 4th, 2024
Join now to see all